G1 Therapeutics (NASDAQ:GTHX) Downgraded to Sell at BidaskClub

G1 Therapeutics (NASDAQ:GTHX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Needham & Company LLC set a $74.00 price target on G1 Therapeutics and gave the company a “buy” rating in a report on Monday, September 30th. B. Riley set a $55.00 price objective on G1 Therapeutics and gave the stock a “buy” rating in a research report on Friday, September 27th. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. raised G1 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $38.00 to $45.00 in a report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $56.67.

Shares of G1 Therapeutics stock opened at $20.95 on Tuesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 14.28 and a quick ratio of 14.28. The firm has a 50 day simple moving average of $22.22 and a 200 day simple moving average of $26.61. G1 Therapeutics has a fifty-two week low of $13.87 and a fifty-two week high of $41.80. The firm has a market cap of $811.76 million, a P/E ratio of -8.18 and a beta of 2.17.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.01. On average, sell-side analysts expect that G1 Therapeutics will post -3.29 EPS for the current year.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. increased its holdings in G1 Therapeutics by 27.4% in the second quarter. BlackRock Inc. now owns 2,468,415 shares of the company’s stock valued at $75,681,000 after purchasing an additional 530,999 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of G1 Therapeutics by 5.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,976,615 shares of the company’s stock valued at $60,603,000 after acquiring an additional 100,523 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of G1 Therapeutics by 27.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,429,138 shares of the company’s stock valued at $44,446,000 after acquiring an additional 310,614 shares during the last quarter. Rhenman & Partners Asset Management AB raised its position in shares of G1 Therapeutics by 95.3% in the 3rd quarter. Rhenman & Partners Asset Management AB now owns 535,657 shares of the company’s stock valued at $12,202,000 after acquiring an additional 261,383 shares during the period. Finally, Redmile Group LLC raised its position in shares of G1 Therapeutics by 33.5% in the 3rd quarter. Redmile Group LLC now owns 390,934 shares of the company’s stock valued at $8,905,000 after acquiring an additional 98,200 shares during the period. Institutional investors and hedge funds own 77.78% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Read More: How big is the FinTech market?

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.